1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United Kingdom >
  5. Essential Pharma Acquires Renaissance Pharma

M&A Deal Summary

Essential Pharma Acquires Renaissance Pharma

On April 2, 2024, Essential Pharma acquired life science company Renaissance Pharma

Acquisition Highlights
  • This is Essential Pharma’s 1st transaction in the Life Science sector.
  • This is Essential Pharma’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2024-04-02
Target Renaissance Pharma
Sector Life Science
Buyer(s) Essential Pharma
Deal Type Add-on Acquisition

Target

Renaissance Pharma

Altrincham, United Kingdom
Renaissance Pharma is a clinical-stage pharmaceutical company focused on the development of life changing therapies in paediatric rare disease, with its lead asset being Hu14.18K322A (Hu14.18) – an immunotherapy currently in Phase II clinical development for the treatment of high-risk neuroblastoma (HRNB). Renaissance Pharma was founded in 2023 and is based in Altrincham, England.

Search 214,503 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Essential Pharma

Egham, United Kingdom
Category Company
Founded 2011
Sector Life Science
DESCRIPTION

Essential Pharma is a specialty generic pharma business focussed on CNS and other niche pharmaceutical products. Essential addresses the problem of drug shortages by ensuring the continued supply of low volume and legacy drugs with high clinical importance which are at risk of discontinuation and stockouts. Essential Pharma was established in 2011 and is based in Egham, United Kingdom.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: United Kingdom M&A 1 of 1
Year: 2024 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal